Semax: Cognitive Research and Limitations

What it is

Semax is a short lab-made peptide, a chain of seven amino acids, copied from a piece of a natural hormone called ACTH. The piece it copies, known as ACTH(4-10), is the part linked to memory and attention rather than the part that drives the adrenal glands.

It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, starting in the 1980s. The designers added three extra amino acids (Pro-Gly-Pro) to one end. That change stops the body from breaking the molecule down in minutes and stretches its working life to hours.

Russia approved Semax in the late 1990s. Doctors there prescribe it as a nasal spray, in strengths from 0.1% to 1%, for cognitive impairment, stroke recovery, and optic nerve disease. It is not approved anywhere in the West.

What it is studied for

Semax has been studied for attention and memory problems, including those caused by poor blood flow to the brain, head injury, and aging. It has also been tested as an add-on treatment in the first days after an ischemic stroke, the kind caused by a blocked blood vessel.

Its third clinical use in Russia is optic nerve atrophy, a condition where the nerve carrying signals from the eye slowly wastes away. In animals, researchers have mostly looked at learning, memory, and brain chemistry.

What the evidence actually shows

In humans

The human data come almost entirely from Russian research groups. A 1996 study reported that Semax showed nootropic-like activity in people, meaning measurable gains in attention and memory (Kaplan et al., 1996). Russian clinical reports describe better attention, memory, and information processing in patients with cognitive impairment.

For stroke, Russian data report better neurological outcomes and faster recovery when a 1% spray is given within the first hours to days (Gusev et al., 2005). The proposed reason is that Semax protects brain tissue that is starved of blood but not yet dead.

For optic nerve disease, Russian clinical reports describe improved vision in some patients. We could not find a study of this use that meets current Western standards.

These are real findings, but they need context. Most of the studies were small, usually under 100 people, and many were open-label, meaning patients and doctors knew who got the drug. Placebo controls and full statistical methods are often not available, because the papers appeared in Russian journals that Western databases do not index. No group outside Russia has repeated the trials.

Study lengths matched the standard Russian course of 10 to 14 days, so they say little about longer use. One more gap: no published study has properly measured how much Semax reaches the human brain from a nasal spray.

Selank, Semax’s sister peptide from the same institute, has the same problem: interesting Russian data and little independent verification. For why this pattern is so common, see why most peptide evidence is preclinical.

In animals

The animal research is broader and easier to judge, because lab methods for rodents are fairly standard worldwide.

Semax raised levels of BDNF, a protein that helps brain cells survive and form new connections, in the hippocampus and basal forebrain of rats (Dolotov et al., 2006). The effect grew with the dose and lasted after dosing stopped. That pattern suggests a change in gene activity rather than a passing drug effect, though the exact chain of events from Semax to BDNF has not been mapped.

Rats given 50 to 600 mcg/kg did better on standard learning tests, including passive avoidance, the Morris water maze, and object recognition, after both single and repeated doses (Levitskaya et al., 2004).

Semax also raised dopamine levels and dopamine turnover in the reward and motivation centers of rodent brains. Dopamine is a chemical messenger tied to drive and focus. Semax seems to raise it indirectly, rather than by acting on dopamine the way stimulants do, though how a short peptide manages this is not fully understood (Eremin et al., 2005). It changed serotonin metabolism as well. Whether that matters for mood in people is unknown.

In a rat model of stroke, Semax changed the activity of more than 100 genes. It lowered inflammatory signals such as IL-1β and TNF-α and shifted genes involved in immune function, blood vessels, and synaptic plasticity (Medvedeva et al., 2014). A compound that touches that many genes is hard to interpret, because it is difficult to tell which changes actually matter.

The usual caution applies. Doses that work in rats do not reliably predict doses in people, and a rat learning test captures a narrow slice of human thinking.

From user reports

People who use Semax report a shift in focus within 15 to 30 minutes of a nasal dose. They tend to describe the effect as clear rather than jittery, without the racing heart or crash of stimulants. Some report increased anxiety at higher doses. Others describe a flat, low-motivation stretch after stopping a long course. These are personal accounts, not measurements.

Users also discuss two modified versions, N-Acetyl Semax and N-Acetyl Semax Amidate, as stronger or longer-lasting. There is no published research on either one. Everything on this page applies to plain Semax. A modified molecule can behave differently in ways nobody has tested, including its side effects.

How it is used in studies

The route in Russian clinical practice, and in nearly all published research, is nasal. The spray goes into the nose because that path reaches the brain along the olfactory and trigeminal nerves and skips the liver. The standard product is 0.1% Semax; the 1% strength was used in stroke research.

Russian protocols describe 2 to 3 drops per nostril, 2 to 3 times a day. That works out to roughly 200 to 600 mcg per dose and 600 to 1,800 mcg per day, given in 10 to 14 day courses that are sometimes repeated after a break.

Rodent studies used 50 to 600 mcg/kg (Levitskaya et al., 2004).

People who use it outside clinical settings report subcutaneous injections of 200 to 1,000 mcg once or twice a day for 10 to 30 days, and cycles of 2 to 4 weeks on and 1 to 2 weeks off. Injection has never been studied. Whether tolerance builds with continuous use is not known; some users report steady effects and others report diminishing returns. None of this is a dosing recommendation.

Side effects and unknowns

The reported side effects are mild. Nasal irritation is the most common, followed by headache at higher doses. Some people report restlessness or anxiety, especially alongside stimulants. Taken late in the day it can cause insomnia. A few report low motivation after stopping a long course, and nobody knows whether that is withdrawal or simply a return to baseline.

Semax does not raise cortisol or stimulate the adrenal glands at studied doses. The piece of ACTH that does that, positions 1 to 3, was left out on purpose. We could not find reports of physical dependence.

The unknowns are bigger than the knowns. Safety data cover 10 to 14 day courses; no one has systematically studied months of continuous use. Drug interaction data are sparse, so combining Semax with psychiatric medicines, especially MAO inhibitors or dopamine-acting drugs, is uncharted territory. Safety in pregnancy, breastfeeding, and children has not been established. No trial has compared Semax head to head with an established cognitive drug, or even with caffeine.

For broader context, see our peptide safety guide and how to read peptide claims critically.

Legal status

In Russia, Semax is an approved prescription medicine, sold as a nasal spray for cognitive and neuroprotective use.

In the United States it is not FDA approved and not a controlled substance. It is sold as a research chemical. The European Union has not approved it either, and it is sold as a research chemical in most EU countries.

Semax is not on the WADA Prohibited List, although ACTH itself is banned. The distinction rests on Semax having no adrenal effect.

Bottom line

Semax has real but thin human evidence: small Russian trials in cognitive impairment and stroke that no one else has repeated. The animal data on BDNF and learning are more solid and explain why people are interested. If you want a cognitive peptide with Western-standard safety and efficacy data, this is not it.

Frequently Asked Questions

Is Semax a stimulant?

Not in the usual sense. It does not block dopamine reuptake or act on adenosine the way stimulants do. Its effect on dopamine is indirect, and some users do find the alertness stimulant-like. It does not produce the cardiovascular strain, appetite loss, or crash that stimulants can.

How quickly does Semax work?

Users report noticeable effects within 15 to 30 minutes of a nasal dose. The BDNF-related changes seen in animals build over days to weeks, because they depend on shifts in gene activity rather than an immediate drug effect.

Can Semax be used with Selank?

The pairing is common in nootropic communities, with Semax for focus and Selank to take the edge off anxiety. No clinical data exist on the combination. The logic is plausible and unverified.

How does Semax compare to modafinil?

They work differently and have very different evidence behind them. Modafinil is an FDA-approved wakefulness drug with large trials; it keeps you alert by acting on dopamine and other wake systems, and it can raise heart rate and cut sleep. Semax has no direct wakefulness effect. The small Russian studies point to attention and memory, and the animal work points to BDNF, a brain growth signal. People who use both describe modafinil as the stronger, harsher push and Semax as milder, without the crash. No study has compared them head to head.

Is N-Acetyl Semax better than regular Semax?

Nobody knows. There is no published research on N-Acetyl Semax or N-Acetyl Semax Amidate. Their popularity rests on theoretical arguments about absorption and on user reports. All the data on this page are for unmodified Semax.

Does Semax affect cortisol?

Not at studied doses. Semax keeps the cognitive fragment of ACTH (positions 4 to 10) and drops the adrenal-stimulating fragment (positions 1 to 3). That was a deliberate design choice.

Why isn’t Semax approved outside Russia?

The large, multi-center Phase III trials that the FDA or EMA require have never been run. That comes down to cost, which runs into hundreds of millions of dollars, to patents, and to the fact that Russian approval does not transfer. See why most peptide evidence is preclinical.

References

1. Dolotov OV, et al. “Semax, an analogue of ACTH(4-10) with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus.” Int J Dev Neurosci. 2006;24(4-5):283-289. PubMed
2. Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500. PubMed
3. Medvedeva EV, et al. “The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228. PubMed
4. Kaplan AY, et al. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neurosci Res Commun. 1996;19(2):115-123. PubMed [research needed, exact PMID to verify]
5. Gusev EI, et al. “Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency.” Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. PubMed [research needed, exact PMID to verify]
6. Levitskaya NG, et al. “Investigation of the spectrum of physiological activities of the peptide Semax.” Neurosci Behav Physiol. 2004;34(8):795-800. PubMed [research needed, exact PMID to verify]
7. Ashmarin IP, et al. “Glyprolines and their analogues.” Biochemistry (Mosc). 2002;67(2):184-194.
8. Agapova TY, et al. “The neuroprotective effect of Semax in conditions of global cerebral ischemia.” Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(4):52-55. [research needed]

See also

• Peptide
  DSIP (Delta Sleep-Inducing Peptide): Research, Mechanism, and Evidence for Sleep Modulation

  DSIP is a nine-amino-acid peptide your body makes, found in 1977, studied for deepening slow-wave sleep and calming stress hormones. The human studies are small and decades old, and nobody has ever found its receptor.

• Peptide
  Epithalon (Epitalon): Research, Mechanism, and a Careful Look at the Anti-Aging Evidence

  Epithalon is a four-amino-acid peptide from a Russian lab, studied for switching on telomerase and restoring melatonin. It lengthened telomeres in a dish and extended lifespan in mice, and it has never been tested for aging in people.

• Peptide
  Selank: Research, Mechanism, and Clinical Evidence for Anxiety and Cognition

  Selank is a seven-amino-acid peptide, a stabilized version of an immune fragment called tuftsin, approved in Russia as a nasal spray for anxiety. Small Russian trials found it worked about as well as a benzodiazepine without the sedation.